Lipocine (NASDAQ: LPCN) is one of 295 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Lipocine to similar companies based on the strength of its earnings, institutional ownership, dividends, profitability, valuation, analyst recommendations and risk.
This table compares Lipocine and its rivals’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Insider & Institutional Ownership
25.8% of Lipocine shares are owned by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 11.3% of Lipocine shares are owned by company insiders. Comparatively, 17.0% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Volatility and Risk
Lipocine has a beta of 2.02, suggesting that its stock price is 102% more volatile than the S&P 500. Comparatively, Lipocine’s rivals have a beta of 6.66, suggesting that their average stock price is 566% more volatile than the S&P 500.
This is a breakdown of current ratings and recommmendations for Lipocine and its rivals, as reported by MarketBeat.
||Strong Buy Ratings
Lipocine currently has a consensus target price of $24.67, suggesting a potential upside of 604.76%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 38.01%. Given Lipocine’s stronger consensus rating and higher possible upside, equities analysts plainly believe Lipocine is more favorable than its rivals.
Earnings & Valuation
This table compares Lipocine and its rivals top-line revenue, earnings per share and valuation.
Lipocine’s rivals have higher revenue and earnings than Lipocine. Lipocine is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Lipocine rivals beat Lipocine on 7 of the 12 factors compared.
Lipocine Company Profile
Lipocine Inc. is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs. Its lead product candidate, LPCN 1021, is an oral testosterone replacement therapy (TRT), designed for twice-a-day dosing and is in Phase III testing. The Company’s additional pipeline candidates include LPCN 1111, an oral testosterone therapy product targeted for once daily dosing, which is in Phase II testing, and LPCN 1107, an oral therapy for the prevention of preterm birth, which is in Phase I testing. These products are based on its Lip’ral promicellar drug delivery technology platform. Lip’ral promicellar technology is a technology based on lipidic compositions, which form an optimal dispersed phase in the gastrointestinal environment for improved absorption of insoluble drugs.
Receive News & Ratings for Lipocine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.